Provectus CEO converts note into 24,544 preferred shares

Each Series D-1 preferred share is convertible into 10 common shares, and the preferred stock will automatically convert on December 31, 2028 unless converted earlier.

Available on EDGAR 10/30/2026 - 11:32 AM EDT Accepted by SEC EDGAR 10/30/2026 - 11:32 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Provectus Biopharmaceuticals, Inc. CEO, director and 10% owner Edward Pershing reported the conversion of his 8% unsecured convertible promissory note into 24,544 Series D-1 Convertible Preferred Stock shares on October 30, 2026, at $2.862 per share. The preferred shares are convertible into 245,440 common shares at 10 common shares per preferred share. His reported position following the transaction was 3,030,677 shares; no Rule 10b5-1 plan was reported.

Insider Trade Summary

24,544 shares exercised/converted

Exercise 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note F3, F4	--	$0.00	--
Exercise	Series D-1 Convertible Preferred Stock F1, F2	24,544	$0.00	$0.00

Holdings After Transaction: Series D-1 Convertible Preferred Stock — 3,030,677 contracts (Direct)

Holdings Before and After: Series D-1 Convertible Preferred Stock, 3,006,133 to 3,030,677 contracts (Direct)

Footnotes (4)

1. F1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
2. F2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
3. F3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
4. F4. On October 30, 2026, the 2025 Note converted into 24,544 shares of Series D-1 Preferred Stock.

Key Figures

Series D-1 preferred shares acquired: 24,544 shares Conversion price: $2.862 per share Underlying common shares: 245,440 common shares +3 more

6 metrics

Series D-1 preferred shares acquired 24,544 shares Conversion on October 30, 2026

Conversion price $2.862 per share Conversion of the 8% unsecured convertible promissory note

Underlying common shares 245,440 common shares Underlying the 24,544 Series D-1 preferred shares

Common shares per preferred share 10 common shares Conversion ratio for Series D-1 preferred stock

Reported resulting position 3,030,677 shares Following the reported transaction

Note interest rate 8% The unsecured convertible promissory note

Key Terms

8% unsecured convertible promissory note, Series D-1 Convertible Preferred Stock, Certificate of Designation, 2025 Financing

4 terms

8% unsecured convertible promissory note financial

"outstanding principal and interest of the 8% unsecured convertible promissory note"

Series D-1 Convertible Preferred Stock financial

"The Series D-1 Convertible Preferred Stock will automatically convert"

Certificate of Designation financial

"in accordance with the terms of the Certificate of Designation"

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

2025 Financing financial

"The 2025 Note was issued pursuant to the Issuer's 2025 Financing"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PVCT CEO Edward Pershing receive in the October 2026 conversion?

Edward Pershing's 8% unsecured convertible promissory note automatically converted on October 30, 2026, into 24,544 Series D-1 Convertible Preferred Stock shares at $2.862 per share. Those preferred shares are convertible into 245,440 common shares.

When will PVCT's Series D-1 preferred shares automatically convert?

The Series D-1 preferred shares will automatically convert into common stock on December 31, 2028, unless converted earlier into common stock in accordance with the Certificate of Designation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	10/30/2026		M			$65,000	10/30/2025	10/30/2026	Series D-1 Convertible Preferred Stock(3)(4)	24,544	$0	$560,000	D
Series D-1 Convertible Preferred Stock	(1)	10/30/2026		M		24,544		10/30/2026	(2)	Common Stock	245,440	$0	3,030,677	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On October 30, 2026, the 2025 Note converted into 24,544 shares of Series D-1 Preferred Stock.

	/s/ Ed Pershing	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)